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Purpose: The aim of this experimental study is to evaluate the efﬁcacy of a novel intraarticular drug in a
papain induced osteoarthritis (OA) rat model and compare with the traditional hyaluronat (HA) visco
supplementation.
Methods: An early stage OA model was induced by the intra-articular injection of papain enzyme in the
right knee joints of 44 Sprague-Dawley rats. Eleven rats (eleven right knees: papain group, 11 left knees:
control group) were chosen randomly 28 days after the last injection and sacriﬁced for verifying OA. The
remaining rats (n ¼ 33) were randomly divided into 3 groups. Group 1 was injected 0,2 mL of sterile
saline solution (0,9%), group 2 was injected 0,2 mL HA and the group 3 was injected 0,2 mL of HA-CSNAG
(hyaluronat, chondritin sulfate, N-acetyl-D-glucosamine) combination in the right knees. Injections were
performed on the 35th, the 42nd and the 49th days consecutively. Two weeks after the last injection, all
groups were sacriﬁced to evaluate the severity of OA according to Mankin system.
Results: Early stage of OA was veriﬁed regarding total Mankin scores (p < 0.05). There was statistically
signiﬁcant difference between Group 1 and Group 2 (p < 0.05), between Group 1 and Group 3 (p < 0.05)
on the 63th day regarding total Mankin scores. Group 3 showed statistically signiﬁcant improvement in
terms of proteoglycan content of matrix when compared to Group 2 (p < 0,05).
Conclusion: HA-CS-NAG compound in hydrogel form is more chondroprotective to rats' cartilage when
compared to HA during the early stages of OA.
© 2016 Turkish Association of Orthopaedics and Traumatology. Publishing services by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Osteoarthritis (OA) is one of the most prevalent and debilitating
joint disease associated with reduced quality of life and increased
healthcare costs. With respect to recent applications of histopath-
ological and imaging techniques, OA is now considered a hetero-
geneous chronic disease that may affect all tissues of the synovial
joint. A large cascade of events lead to the breakdown and loss of
articular cartilage, resulting in the damage of all structures of theür).
ciation of Orthopaedics and
s and Traumatology. Publishing sejoint including subchondral bone change, varying degrees of
osteophyte formation, synovitis and adjacent supporting connec-
tive tissue elements.1
Available medical therapies, including traditional analgesics and
non-steroidal anti-inﬂammatory drugs (NSAIDs) for OA are inef-
fective at altering or slowing down the disease progression and
rather alleviate the symptoms by reducing pain and improving the
joint mobility. Additionally, their chronic use has been limited by
their deleterious side effects.2,3 However, various agents including
cartilaginous matrix precursors (hyaluronat [HA], chondroitin sul-
fate [CS], glucosamine [GA]) and cytokine modulators are currently
being investigated for their effects on both symptoms and joint
structural degradation. These molecules are expected to limit the
progression of the disease by affecting the pathological changes inrvices by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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positive effects in pain relief and joint functional improvement, the
use of viscosupplementation (HA, CS and GA) to treat OA is growing
worldwide.5 In addition to HA having potentially chon-
droprotective effects within the joint, CS and GA play an important
role in maintaining joint homeostasis6 and they both have oral and
intra-articular injectable forms. Some authors make a point of low
bioavailability and potential side effects, including systemic
toxicity, impaired glucose tolerance and gastric ulceration of these
nutraceuticals when taken orally.7,8 Moreover, the limitations of
these drugs, such as protein hypersensitivity of the synovium may
have a negative effect on the intra-articular route. Also, the drugs
that are injected intra-articularly may be rapidly cleared of the
synovial ﬂuid, thus obviating the advantage of direct delivery.
Ideally, the drug should be delivered directly inside the affected
joint in order to achieve a high intra-articular concentration and
have limited systemic toxicity.3
For this purpose, many pharmacologically active drugmolecules
are under investigation. Recently, an intra-articular injectable
hydrogel form of a compound of HA (36 mg/2.25 mL), CS (45 mg/
2.25 mL) and N-Acetylglucosamine (NAG) (9 mg/2.25 mL) has been
introduced, to achieve long-term drug exposure and low-protein
concentration in order to avoid synovial hypersensitivity reaction
when delivered intra-articularly.
The purpose of this study was to evaluate the efﬁcacy of this
novel intra-articular drug as a structure-modiﬁer and a chon-
droprotective agent in a papain-induced OA rat model and to
compare it to the traditional HA viscosupplementation.
Materials and methods
Study design
All animal experimental research protocols were approved by
the Animal Research Committee and the study was supported by
our Hospital Research Fund. A total of 44 adult female Sprague-
Dawley rats with a mean age of 12 months and weighing be-
tween 250 and 350 g were used. Animals were housed (5 rats/cage)
under standard management conditions. Room temperature and
humidity were maintained at 20e24 C and at 50e60%, respec-
tively. The light cycle was ﬁxed at 12 h and the animals were fed a
standard rat diet with water ad libitum.
Osteoarthritis was induced by intra-articular injection of papain
enzyme (Sigma-P3125; SigmaeAldrich Corp., St. Louis, MO, USA) at
a dose rate of 10 mg in 0.05 M sodium acetate (pH: 4.5) with
enzymatic activity of 31 IU/mg in the right knee joints of the 44
Sprague-Dawley rats on the 1st, 4th and 7th days of the study as
described by Murat et al9 (Fig. 1). On the papain injection days, allFig. 1. Injection to the knee.rats were injected with 0,2 mL of sterile saline solution (0.9%) in the
left knee joints to serve as the control group. On the 35th day, 28
days after the last injection, 11 rats were chosen randomly and
sacriﬁced with high-dose thiopental (200 mg/kg) given intraperi-
toneally. Both the right (papain group) and the left (control group)
knee joints were extra-articularly removed to evaluate the severity
of OA according to histological scoring system.10
On the 35th day, the remaining experimentally OA-induced rats
(n ¼ 33) were randomly divided into three groups, and were given
injections in their right knees as follows; 0,2 mL of sterile saline
solution (0.9%) in Group 1, 0,2 mL of HA (Ostenil®; TRB Chemedica
AG, Munich, Germany) with a meanmolecular weight of 1.2 MDa in
Group 2, and 0,2 mL of HA-CS-NAG combination (sodium hyal-
uronic acid [36 mg/2.25 mL], sodium chondroitin sulfate [45 mg/
2.25 mL] and NAG [9 mg/2.25 mL] (Genvisc™ gplus; Phibio GmbH,
Frankfurt, Germany)) in Group 3. The injections were given again
on the 42nd and 49th days to mimic the clinical use. Two weeks
after the last injection, all groups were sacriﬁced with high dose of
intraperitoneal thiopental (200 mg/kg).
Tissue preparation and histological grading
On each scariﬁcation day, the tibiofemoral joints of the rats were
separated by cutting the tibia and femur, and the attaching liga-
ments and tendons were removed with a surgical blade. Femoral
condyles and tibia samples were ﬁxed at 10% buffered formalin and
decalciﬁed in 8% formic acid. After dehydration through a graded
series of ethanol solutions, the specimens were embedded in
parafﬁn. The frontal parts were sectioned at 4 mm thickness. Each
specimen was evaluated using the modiﬁed Mankin's histological
grading system.11 Hematoxylin and eosin stains were used to
evaluate the structure, the chondrocytes, tidemark and pannus
formation. Loss of proteoglycan staining intensity was assessed by
Toluidine blue staining. Samples were examined and assessed
independently by two blinded investigators.
Statistical analysis
Interobserver reliability was evaluated using two-way random,
absolute agreement method. Data were evaluated using the SPSS
for Windows 21.0 (SPSS Inc., Chicago, IL, USA) software. Before
starting the study, a power analysis using pilot datawas performed.
This analysis determined that with a 95% conﬁdence interval and a
power of 80%, 11 animals per group would be required. The Krus-
kaleWallis and Dunn tests were used for the comparisons of the
parameters. An alpha level of 0.05 was chosen to judge statistical
signiﬁcance.
Results
Statistically signiﬁcant differences were found between the
control group (11 left knees) and papain-injected group (11 right
knees) regarding total Mankin scores (control: 3.91, papain: 14.0;
p < 0.001) (Table 1). Representative histological lesions in the
cartilage of OA-induced rats were; moderate and severe surface
irregularities, cleft formation in the transitional and radial zone,
hypercellularity and disrupted columns of chondrocytes and
multilayered tidemark. On the 63rd day, lesions were not reduced
and got worse in Group 1. Representative histological lesions in
Group 1 were; loss of severe matrix loss, moderate pannus for-
mation, all of the above and large patches of cell death and
sloughing of layers till mid-zone (Figs. 2 and 3). On the 63rd day,
there was a statistically signiﬁcant difference between Group 1 and
Group 2, between Group 1 and Group 3 regarding total Mankin
scores (Group 1: 20.27, Group 2: 10.2, Group 3: 7.18) (Figs. 4 and 5).
Table 1
Mean and total scores of the groups.
Fig. 2. (a) Characteristics of a normal articular structure: intact surface layer, normal morphology and distribution of chondrocytes and a continuous matrix within them. (b)
Proteoglycan matrix showing diffuse staining with accentuation in perichondrial areas (Toluidine blue).
Fig. 3. Images from Group 1 (saline-treated knees) (a) Extensive loss of the transitional and radial zone (arrows) as well as hypocellularity in the residual chondroid structure
(asterisk) and cell deaths. (b) Prominent loss of proteoglycan matrix manifesting as pale areas in Toluidine blue staining.
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Fig. 4. (a) A vertical cleft extends through the transitional and radial zone (arrow), slightly irregular surface layer, cluster of cells focally as well as hypocellularity and cell deaths. (b)
Moderate loss of proteoglycan matrix in Group 2 stained with Toluidine blue (asterisk).
Fig. 5. (a) Mild to moderate degree of surface irregularity (arrows). Hypercellularity due to chondrocyte proliferation with minimal clustering. (b) Minimal loss of proteoglycan
matrix in Group 3 stained with Toluidine blue.
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the proteoglycan content of matrix when compared to Group 2
(p < 0.05). Descriptive histological lesions with scores are pre-
sented in Tables 2 and 3.
Discussion
Structure-modifying drugs including HA, CS and GAs are
thought to be potentially effective as chondroprotectives by
altering the catabolic and anabolic balance of the joint.11 These
drugs are candidates for intra-articular use, due to either their poorTable 2
Mean posttreatment scores of the groups according to the Mankin system.
Sacriﬁcation at 28th day
Control Papain induced
Cartilage structure 2.45 ± 0.93 5.27 ± 0.65
Cells distribution and density 0.91 ± 0.54 4.09 ± 0.54
Toluidine blue staining 0.55 ± 0.52 2.36 ± 0.67
Tidemark integrity e 1.00 ± 0.63
Pannus formation e 1.27 ± 0.65
Total Mankin score 3.91 ± 1.04 14.0 ± 1.79
Table 3
Comparison of the groups.
Total Mankin score Cartilage structure Cells distribut
Papain/control p < 0.001 p < 0.001 p < 0.001
HA/saline p < 0.05 p < 0.05 p < 0.05
HA-CS-NAG/saline p < 0.001 p < 0.001 p < 0.001
HA-CS-NAG/HA p > 0.05 p > 0.05 p > 0.05oral bioavailability or concern for systemic toxicity.3 Despite the
presence of many studies on the intra-articular use of HA, oral NAG
and CS combination, there is limited experimental data to evaluate
the intra-articular application and its effects on hyaline cartilage of
these drugs.
The purpose of this experimental study was to evaluate the
structure-modifying and chondroprotective effect of an intra-
articular injectable hydrogel form of a compound of HA, NAG and
CS, through histopathological parameters.
In our study, an early-stage OA model was produced by intra-
articular application of papain which is a proteolytic enzyme.Sacriﬁcation at 63rd day
Saline treatment HA treatment HA-CS-NAG treatment
6.27 ± 0.65 3.64 ± 0.67 2.18 ± 0.40
6.91 ± 0.94 2.55 ± 0.82 2.00 ± 0.77
3.09 ± 0.54 1.55 ± 0.52 1.09 ± 0.30
2.09 ± 0.54 1.45 ± 0.52 1.36 ± 0.50
1.91 ± 0.54 0.82 ± 0.40 0.55 ± 0.52
20.27 ± 1.79 10.02 ± 1.54 7.18 ± 0.98
ion and density Toluidine blue staining Tidemark integrity Pannus
p < 0.001 p > 0.05 p < 0.05
p < 0.05 p > 0.05 p < 0.05
p < 0.001 p > 0.05 p < 0.05
p < 0.05 p > 0.05 p > 0.05
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teoglycans in the extracellular matrix (ECM)12; it does not have a
direct impact on collagen and chondrocytes.13 It has been reported
that papain also did not impair the regenerationmechanisms of the
cartilage and that the regeneration potential was inversely pro-
portional with the applied dose.12,14 Quantiﬁcation of the papain-
induced OA in rodent models was developed in relation to pro-
gression of lesions with days. Thus, it is possible to grade OA and
evaluate the available treatment options in these grades. This
model has been well accepted and demonstrated that, on Day 28,
the observed lesions were consistent with early osteoarthritic
changes in humans.9,15
In our experimental model of OA, the scores in each subcategory
of Mankin scoring system, including articular cartilage surface, cell
distribution and density, Toluidine blue staining (proteoglycan
content of matrix), integrity of tidemark and pannus formation
were statistically signiﬁcant when compared to the control group
and consistent with those of early-stage OA, similar to
literature.9,15,16
Again in our early-stage OA model, HA and HA-CS-NAG com-
pound have provided a statistically signiﬁcant improvement in the
articular surface and matrix proteoglycan content. HA is a critical
glycosaminoglycan for the maintenance of functional and struc-
tural integrity of the joint cartilage. It is one of the main compo-
nents of the synovial ﬂuid; it maintains the viscosity and elasticity
in the knee joint. The comparison of HA and HA-CS-NAG compound
revealed that the proteoglycan content of the matrix in Mankin
subtypes were statistically signiﬁcant in favor of the HA-CS-NAG.
We believe that this is due to NAG and CS content of this new
hydrogel product. CS and NAG are naturally found in the cartilage
matrix, synovial ﬂuid and major components of ECM where they
constitute an important part of proteoglycans. They are primarily
thought to provide building blocks for the biosynthesis of cartilage
ECM by chondrocytes.17
In many in vitro studies, endogenous HA has been shown to
increase proteoglycan and collagen synthesis, reduce chondrocytes
apoptosis and stimulate the metalloproteinase tissue inhibitor.18
Some investigators suggest that HA exerts this effect with inhibit-
ing nitric oxide production and this might be a mechanism for the
therapeutic effect of HA.19 In addition to chondroprotective effect of
HA, it has been shown that NAG inhibits nitric oxide,
cyclooxygenase-2, and IL-6 production which in turn reduce
apoptosis in cultured human chondrocytes.20 CS can also reduce
apoptosis of chondrocytes via mitochondrial pathway.21
In our study, histopathological evaluation revealed statistically
signiﬁcant healing of cellular abnormality in the HA and HA-CS-
NAG groups when compared to the saline group, similar to the
literature. Although the HA-CS-NAG group had better results in
healing cellular abnormality, no signiﬁcant difference was found
when compared to the HA group. At the junction of the hyaline
cartilage and adjacent subchondral bone, in the areawhich is called
‘tidemark’, a remnant of calciﬁed cartilage is present. As OA pro-
gresses, vascular invasion and advancement of this zone of calciﬁed
cartilage into the articular cartilage occur and this process further
contributes to a decrease in the articular thickness.22 The effects of
synovial inﬂammation likely contribute to the dysregulation of
chondrocyte function in an analogous fashion, favoring a disequi-
librium between the catabolic and anabolic activities of the chon-
drocyte in remodeling the cartilage ECM.23 With regards to the
tidemark and synovial membrane, there were no statistically sig-
niﬁcant differences between the treatment and saline groups. Since
the study was conducted in an early model of OA, this was probably
due to the fact that both tidemarks (indistinctly and vascular in-
vasion) and moderate or severe synovial membrane inﬂammatory
changes are present at the advanced steps of OA. Many clinical andexperimental studies have demonstrated the efﬁcacy of CS and GA
in treating cartilage degeneration and OA in both animals and
humans. However, in almost all of these studies, CS and GA have
been administered orally.8,24,25 Some authors and guidelines make
a point of low bioavailability of GA and CS when taken orally. CS has
a very low bioavailability; typically 10e15% in the body.24 When
taken orally, most of the GA and CS are lost in the digestive track.
This is why it may take a long time to beneﬁt from capsules, tablets
and liquids. Therefore, oral GA carries the risk of ‘excess gastric
acidity’ leading to what is now known as ‘glucosamine allergy’
(gastric irritation, wheezing, constipation and gastric ulceration).26
Moreover, it is demonstrated that dietary supplement of GA has
side effects such as acute liver injury, insulin resistance and
impaired glucose tolerance, and increased intra-orbital pres-
sure.7,8,27 There are studies concerning more effective and practical
administration of these molecules that have chondroprotective
effects as demonstrated in numerous studies. These studies are also
aimed at increasing the bioavailability and avoiding side effects.
Currently, it has been shown that intra-articular HA, NAG and CS
administration is safe and efﬁcacious in OA trials, experimental
animal models and in vitro studies.28e30 Overall, our microscopic
evaluation revealed the chondroprotective effect of intra-articular
HA-CS-NAG compound in hydrogel form in an experimental OA
model, with respect to preserving and healing articular surfaces,
cellular abnormality and proteoglycan content when compared to
the groups treated with saline or HA.
The main drawback of our study which precludes reaching a
more deﬁnite judgement was that the Mankin scoring system is a
semi-quantitative histomorphometric assessment method and its
results are subjective. Further studies investigating the quantiﬁca-
tion of proteoglycan or Type 2 collagen are essential and should be
required.
In conclusion, HA-CS-NAG compound in hydrogel form is more
chondroprotective to rats' cartilage when compared to HA during
the early stages of OA. The HA-CS-NAG compound group showed
statistically signiﬁcant difference regarding the proteoglycan con-
tent of ECM.
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